Floatz logo

Etbx-011

Thyroid Cancer

NantCell, Inc.vaccinePhase 1/2Dormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
13/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
ALECTINIB
Hoffmann-La Roche
Phase 2B
Denosumab
Amgen
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
[68ga]ga-nota-t4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

Etbx-011 is also rated in:

non-small cell lung carcinomaDormant
C
Indicative ·
35 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
35 / 100
View asset →
colon carcinomaDormant
D
Indicative ·
31 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →